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Abstract 1 
The N-terminal domain (WH1) of the Pseudomonas pPS10 plasmid DNA replication protein RepA 2 
can assemble into amyloid fibers in vitro and, when expressed in Escherichia coli, leads to a unique 3 
intracellular amyloid proteinopathy by hampering bacterial proliferation. RepA-WH1 amyloidosis 4 
propagates along generations through the transmission of aggregated particles across the progeny, 5 
but it is unable to propagate horizontally as an infectious agent, thus being the first synthetic 6 
bacterial prionoid. RepA-WH1 amyloidosis is promoted by binding to dsDNA in vitro and it is 7 
modulated by the Hsp70 chaperone DnaK in vivo. Different mutations in the repA-WH1 gene result 8 
in variants of the protein with distinct amyloidogenicity. Here we describe that intracellular 9 
aggregates of the hyper-amyloidogenic RepA-WH1(A31V) variant are able to induce and enhance 10 
the growth in vivo of new amyloid particles from molecules of wild-type RepA-WH1, which 11 
otherwise would remain soluble in the cytoplasm. On the contrary, RepA-WH1(∆N37), a variant 12 
lacking a clear amyloidogenic sequence stretch that aggregates as conventional inclusion bodies 13 
(IBs), can drive the aggregation of the soluble protein into IBs only if expressed at high molar ratios 14 
over RepA-WH1(WT). The cytotoxic bacterial intracellular prionoid RepA-WH1 thus exhibits a 15 
hallmark feature of amyloids, as characterized in eukaryotes: cross-aggregation between variants of 16 
the same protein. 17 
18 
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Introduction 1 
Amyloid proteinopathies are neurodegenerative and systemic diseases with increasing incidence in 2 
human population, currently being one of the main burdens associated with aging. Although protein 3 
amyloidoses have broad clinical manifestations, they share a common aetiology: the accumulation of 4 
insoluble aggregates of a particular protein, either misfolded or post-translationally processed, which 5 
are made of crossed-β sheet assemblies, the signature three-dimensional structure of amyloids (1). 6 
Oligomers of an amyloidogenic protein, in their pathway towards assembling as fibers, seem to be 7 
the most toxic amyloid species either by targeting membranes, by depleting essential cell factors 8 
through co-aggregation or, indirectly, by contributing to generate reactive oxygen species (2). Apart 9 
from studies carried out with human cells in culture and with mice, which have uncovered many 10 
pathways possibly linked to disease, there is a need for simpler model systems that provide further 11 
insight into the essentials of amyloidosis. These include Drosophila and Caenorhabditis animal 12 
models and, among microorganisms, yeast. Fungal prions have indeed contributed to our knowledge 13 
about the molecular basis for amyloid assembly and propagation (3), but they are not optimal models 14 
for disease because they behave as selectable epigenetic determinants of non-Mendelian inheritance, 15 
conferring beneficial phenotypic traits to their carriers (4). On the same track, a number of natural 16 
amyloids have been recently identified in bacteria and found to be involved in scaffolding 17 
extracellular biofilms or as inert, mobilizable intracellular deposits of toxic peptides, such as 18 
microcins (5). The unsurpassed potential of Escherichia coli as a model system in Biology has also 19 
been exploited to study the heterologous aggregation of amyloidogenic proteins, such as the yeast 20 
prion Sup35p/[PSI+] or Alzheimer's Aβ peptides, which aggregate as intracellular inclusion bodies 21 
(IBs) (6,7). 22 
We have recently found that the N-terminal Winged-Helix domain (WH1) of RepA, a plasmid 23 
DNA replication initiator/transcriptional repressor, when includes a mutation (A31V) recurrently 24 
found to naturally enhance plasmid replication in vivo (8), assembles into amyloid fibers in vitro 25 
upon allosteric binding to small dsDNA effector molecules (9,10). Furthermore, fusions of RepA-26 
WH1(A31V) to a fluorescent protein tag allowed to track the aggregation of the protein in the 27 
  
 
4 
cytoplasm of E. coli, revealing a drastic reduction in cell proliferation upon protein aggregation (11). 1 
Besides such toxicity, RepA-WH1(A31V) aggregates differ from conventional IBs in a higher 2 
degree of staining with a specific amyloidotropic fluorophore and in exhibiting dynamic inter-3 
conversion between distinct amyloid species, which resemble prion strains (12). The latter process is 4 
modulated by the Hsp70 chaperone DnaK that generates oligomeric RepA-WH1(A31V) particles 5 
that are readily transferred to the progeny during bacterial division (12). Being non-infectious but 6 
vertically transmissible from mother to daughter cells, RepA-WH1 qualifies as the first entirely 7 
bacterial prionoid (13). 8 
In this work, by means of the pairwise co-expression of RepA-WH1 alleles coding for proteins 9 
with diverse amyloidogenicity, which were tracked through epitope tags and fusions to fluorescent 10 
proteins with distinct colors, we have addressed how they mutually influence their aggregation in 11 
vivo. We have found that the interplay between their intrinsic aggregation tendencies, expression 12 
levels and intermolecular contacts determines the solubility vs. aggregation balance for each RepA-13 
WH1 variant. 14 
 15 
Materials and Methods 16 
Bacterial strain and plasmid constructs. All experiments were carried out in the E. coli K-12 strain 17 
MDS42-recA, whose reduced genome has been depleted of mobile genetic elements (14), to avoid 18 
inactivation of the repA-WH1 by transposon insertion (11). Plasmids (Table 1) of the red series 19 
expressing either RepA-WH1(A31V) or ∆N37 are derivatives of the RK2-based, low copy number 20 
pSEVA121 vector (http://seva.cnb.csic.es/SEVA) (15) and were described elsewhere (12), while 21 
construction of the WT variant was performed by PCR (Pfu DNApol) using the oligonucleotides 22 
described in Table 2. Plasmids of the yellow series were constructed by consecutive ligation of PCR-23 
amplified fragments carrying the appropriate Ptac-repA-WH1-YFP expression module from pWH1s 24 
(9), but including a cMyc-encoding tag in the 5' primer (Table 2), a downstream lacIq repressor 25 
cassette and the p15A replicon plus the Cm resistance gene (from the pACYC184 vector). 26 
Expression was carried out at 37 oC in LB medium, supplemented with either ampicillin (100 µg.mL-27 
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1; for the red series) or chloramphenicol (30 µg.mL-1; yellow series), at an OD600 nm of 0.2 by means 1 
of the addition of IPTG to 0.5 mM. 2 
Epifluorescence microscopy. Bacteria carrying the fluorescent mCherry/YFP fusion proteins were 3 
observed as described (12), in a Nikon Eclipse 90i microscope equipped with a CFI PLAN APO VC 4 
100x (NA 1.40) oil immersion objective and a Hamamatsu ORCA-R2 CCD camera. The following 5 
excitation (EX) and emission (EM) filters and exposure times were used: m-Cherry (EX 543/22, EM 6 
593/40; 600 ms), YFP (EX 500/24, EM 542/27; 700 ms). In dual color expression experiments, 7 
exposure times were fixed to 1 s. A neutral 1/8 filter was interposed in the optical path in most of the 8 
cases, with the exception of co-transformants involving the mRFP or YFP controls, in which a 1/32 9 
filter was used due to their higher levels of expression. DIC (Differential Interference Contrast) 10 
images were also captured (100-300 ms). Image analysis was carried out with the NIS AR 3.1 11 
software (Nikon). 12 
Protein detection and quantitation. Protein expression levels were determined by means of 13 
Western-blotting, targeting with antibodies the N-terminal peptide tags His6 (mCherry fusions) and 14 
cMyc (fusions to YFP). Cells from 25 mL of culture at OD600 nm of 2.0 were sedimented, lysed and 15 
electrophoresis was run as described (12). Primary mouse antibodies (anti-His, 1:50,000; anti-cMyc, 16 
1:10,000; Sigma) were incubated for 2 h and the HRP-conjugated secondary antibody (1:10,000) for 17 
1 h. Chemiluminiscent detection was performed with the ECL prime kit (GE Healthcare) and band 18 
intensity analysis was carried out, with samples from three independent cultures, using the Quantity 19 
One software (v. 4.6.3; Bio-Rad). 20 
SDD-AGE assay. Semi-Denaturing Detergent Agarose Gel Electrophoresis (16) was carried out as 21 
previously described (12) on whole cell lysates from 25 mL cultures that had been grown for 4h after 22 
IPTG induction (see above). 3 µl samples extracted from cells expressing RepA-WH1(WT)-mCherry 23 
or RepA-WH1(A31V)-YFP, or 9 µl for the co-transformant expressing both proteins, were diluted to 24 
40 µl in 0.5×TAE, 5% glycerol, 1% sarkosyl, 0.1 mg/ml bromophenol blue, plus protease inhibitors 25 
cocktail (Roche). Electrophoresis was run at 50V for 12 h at room temperature. The gel was electro-26 
  
 
6 
blotted to a PVDF membrane and antibody detection was performed as described above, with the 1 
following primary antibodies dilutions: anti-His (1:50,000), anti-cMyc (1:5,000). 2 
 3 
Results and Discussion 4 
The soluble, although weakly amyloidogenic (9), wild-type (WT) RepA-WH1, its hyper-5 
amyloidogenic A31V mutant (9), or a deletion mutant lacking its amyloidogenic peptide stretch 6 
(∆N37) (17) thus aggregating as IBs (12), were cloned either into a low copy-number RK2-based 7 
plasmid vector or into a compatible, medium copy-number p15A replicon. These RepA-WH1 8 
variants were fused, through a flexible linker placed at their C-termini, to monomeric red (mCherry) 9 
or yellow (YFP) fluorescent proteins as well as, at the N-termini of the chimeras, to His6 or cMyc 10 
tags, respectively (Fig. 1). A single point mutation (A206K) was introduced in YFP in order to get a 11 
mostly monomeric variant of the protein (18). Both series of fused genes were cloned under an 12 
inducible Ptac promoter and carried downstream tandem repeats of the specific amyloidogenic 13 
effector DNA sequence opsp18 (11,12). When separately transformed into E. coli, IPTG-induced 14 
expression, followed for up to 4 h, led to the appearance of the characteristic red (Fig. 1A) or yellow 15 
(Fig. 1B) fluorescent labels, which became clear after 30 min of induction. The fused RepA-16 
WH1(WT) protein remained dispersed in the cytoplasm, showing diffused fluorescence, as did the 17 
mCherry or YFP proteins when expressed alone as controls (mRFP/YFP; Fig. 1A). On the contrary, 18 
the RepA-WH1(A31V) hyper-amyloidogenic variant and ∆N37 appeared aggregated in the 19 
cytoplasm, albeit with distinct phenotypes: the former as multiple (mostly 2 or 3) aggregates per cell 20 
and the latter mainly as monopolar IBs, as previously described (12). The relative protein levels in 21 
the soluble (supernatant) and aggregated (pellet) fractions were then quantified by Western blotting 22 
using monoclonal antibodies specific for the fused peptide tags. The expression of RepA-WH1(WT) 23 
led to higher relative levels of soluble protein when fused to YFP (Fig. 1B) than if fused to mCherry 24 
(Fig. 1A), in which a significant aggregated fraction was evident. This observation correlated with a 25 
higher total level of expression for RepA-WH1(WT), and thus an increased tendency towards 26 
aggregation, when cloned in the pRK2 vector than when expressed from p15A (Fig. 1C). However, 27 
the relative levels of expression observed were inverted for the RepA-WH1(A31V) and ∆N37 28 
  
 
7 
variants, which were mostly found aggregated disregarding the vector or fluorescent protein fusion 1 
employed. It is noteworthy that, compared with the wild-type protein, RepA-WH1(A31V) is hyper-2 
amyloidogenic (9) and ∆N37 is a metastable mutant with marginal stability (17), therefore both were 3 
expected to aggregate. These experiments indicated that the combination of RepA-WH1 variants 4 
fused to distinct fluorescent proteins, together with tuned expression levels from compatible vectors, 5 
would provide a suitable platform to perform cross-aggregation studies in vivo, as described in the 6 
next section. 7 
Co-expression of distinct RepA-WH1 pairs under conditions previously established for the 8 
individual proteins (12) led to the accumulation in bacteria of the corresponding red (mCherry) and 9 
yellow (YFP) fluorescence (Fig. 2A). Diffused fluorescence was only appreciated in cells where the 10 
soluble RepA-WH1(WT) variant was simultaneously co-expressed fused to both fluorescent tags. 11 
However, biochemical fractionation of the cells (Fig. 2B) suggests that the diffused fluorescence 12 
usually exhibited by RepA-WH1(WT) might correspond to oligomers susceptible to be sedimented, 13 
rather than to soluble protein. This is coherent with the fact that the wild-type protein is mildly 14 
amyloidogenic (9). Otherwise, the aggregation-prone A31V and ∆N37 variants dominated over the 15 
wild-type, which became aggregated into foci that followed the tendency of the co-expressed 16 
partner: either multiple and dispersed (A31V) or single and monopolar (∆N37) aggregates (Table 3), 17 
being A31V the strongest variant in spite of its level of expression. These results are compatible with 18 
previous experiments in vitro, in which ex vivo purified RepA-WH1(A31V) aggregates drove the 19 
formation of amyloid fibers by soluble molecules of the same variant and nucleated the cross-20 
aggregation of its WT counterpart (11). In this sense, it is worth to note that recent NMR studies 21 
have demonstrated that amyloid aggregates purified from biological sources actually do template, on 22 
soluble protein molecules, the same amyloid conformations they originally adopted (19,20). Using 23 
an amyloidotropic fluorophore (BTA-1) we have previously shown that the aggregates formed by 24 
RepA-WH1 inside bacterial cells indeed are amyloids and, furthermore, a gradation in 25 
amyloidogenicity can be established between distinct amyloid variants (12). To explore if any 26 
additional difference can be found between the aggregated fractions of RepA-WH1(WT) and RepA-27 
WH1(A31V), whole cell lysates bearing these proteins, either separately or co-expressed, were 28 
  
 
8 
analyzed by means of SDD-AGE, a technique widely used to separate distinct aggregated species of 1 
yeast prions (16), that we have previously adapted for RepA-WH1(A31V) aggregates in E. coli (12). 2 
Interestingly, SDD-AGE shows (Fig. 2C) that, in addition to the already reported RepA-3 
WH1(A31V) oligomers (12), RepA-WH1(WT) assembles a distinct oligomeric aggregate, with a 4 
lower electrophoretic mobility than the hyper-amyloidogenic species. This observation actually 5 
resembles what it had been reported on SDD-AGE in yeast prions: phenotypically weak prion strains 6 
tend to form large amyloid assemblies, whereas strong strains assemble amyloid species with more 7 
discrete sizes (21,22). However, it must be noted that, although from the results shown in this work it 8 
is clear that co-expression of distinct RepA-WH1 variants mutually enhances aggregation, our SDD-9 
AGE analysis does not provide evidence for their co-existence in a given type of oligomeric 10 
aggregate. This could be reflecting a limitation of a technique designed for the Q/N-rich (polar) 11 
amyloids assembled by yeast prions, whereas hydrophobic residues are the main drivers of amyloid 12 
aggregation in the case of RepA-WH1 (9). 13 
Measurements of the average cell length in bacterial populations expressing the distinct RepA-14 
WH1 pairs (Table 3) showed that bacteria expressing the RepA-WH1(A31V) variant were 15 
consistently longer (by at least 1 µm) than those bearing combinations of the WT variant and the 16 
∆N37 and mRFP/YFP controls. This is an indication of delayed cell division and thus of the toxicity 17 
of the RepA-WH1(A31V) aggregates (23,24). The significant dispersion in the length of bacteria 18 
bearing RepA-WH1(A31V) reflects their tendency towards filamentation, as previously observed 19 
(11,12). 20 
It is worth to note that, in the case of the variant forming conventional IBs (∆N37), the level of 21 
expression (Fig. 1C) determined its ability to enhance the aggregation of RepA-WH1(WT) (Fig. 2A); 22 
e.g., when expressed from the p15A/YFP vector, high expression of ∆N37 drove the aggregation of 23 
WT into IBs. Since ∆N37 lacks the main amyloidogenic stretch in RepA-WH1 (9), this presumably 24 
occurs through a different region in the protein. On the contrary, its lower relative expression from 25 
pRK2/mCherry resulted in smaller IBs with weak co-localization of RepA-WH1(WT), but with a 26 
vast excess of this yellow-tagged protein dispersedly located in the cytoplasm (Fig. 2A). Therefore, 27 
the aggregation led by RepA-WH1(∆N37) can be regarded as non-specific, most likely based on 28 
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general hydrophobic interactions (17), because in that mutant the main amyloidogenic stretch in 1 
RepA-WH1 is absent (9). Thus, RepA-WH1(∆N37) can either drive the aggregation of a fraction of 2 
RepA-WH1(WT) towards IBs, or become attached to the foci pre-established by RepA-3 
WH1(A31V). 4 
As controls, neither individual mCherry nor YFP proteins expressed under the same conditions 5 
co-aggregated with RepA-WH1s, but remained diffused across the cytoplasm (Fig. 3). It is 6 
interesting to note that, in these controls, the regions occupied by the nucleoid are often excluded of 7 
labeling, either by mCherry or YFP, suggesting that both fluorescent proteins might be forming 8 
oligomers large enough to have reduced diffusion rates inside the crowded nucleoid milieu (25). 9 
The simple co-localization experiments reported here provide evidence for the ability of the 10 
RepA-WH1(A31V) prionoid to induce cross-aggregation in the cytoplasm of E. coli, i.e., to enhance 11 
the growth of amyloid particles by a distinct variant of the same protein with reduced 12 
amyloidogenicity. Such assay easily discriminates bona fide amyloid aggregation from formation of 13 
IBs, which albeit exhibit some amyloid-like character (26,27), differ in cellular distribution and 14 
number, toxicity and chaperone-modulated transmissibility (11,12). Besides the reports on 15 
heterologous expression of human amyloidogenic proteins in E. coli (7) and the pioneering work by 16 
Chapman and Hultgren with the amyloid curli fibers (28), recently adapted by Hochschild and co-17 
workers for the extracellular secretion of proteins (29,30), the RepA-WH1 prionoid constitutes a 18 
fully bacterial system to test intracellular amyloid cross-seeding, a hotspot in current research on the 19 
etiology and pathogenesis of human amyloidosis (31). 20 
 21 
Conclusions 22 
The results presented in our previous reports established that the synthetic bacterial prionoid RepA-23 
WH1 recapitulates some of the universal features of protein amyloidosis: i) It adopts two alternative 24 
conformations, soluble dimers and insoluble monomers, which assemble in vitro as amyloid (cross-25 
β) sheets; ii) it forms intracellular aggregates that hamper bacterial proliferation; iii) amyloid variants 26 
with distinct toxicities and morphologies have been identified in vivo; and iv) those intracellular 27 
  
 
10 
aggregates can seed in vitro the growth of amyloid fibers from soluble RepA-WH1 molecules. 1 
Exploring the influence on amyloidosis of distinct protein fusion tags, expression levels, gene dosage 2 
and allelic variants, we have reported here a fifth feature: the ability of a hyper-amyloidogenic 3 
RepA-WH1 point mutant (A31V) to drive the soluble, mildly amyloidogenic, wild-type protein to 4 
aggregate as intracellular inclusions. Given the reduced toxicity, extracellular location and relaxed 5 
cross-seeding specificity of other bacterial amyloids, RepA-WH1 stands out as a minimal model 6 
system for human amyloid proteinopathies. 7 
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Figure Legends 14 
 15 
Figure 1. Expression in E. coli of single RepA-WH1 variants (WT, A31V or ∆N37) fused to red 16 
(mCherry/mRFP) (A) or yellow (YFP) (B) fluorescent protein tags. Left: Microscopy imaging 17 
(fluorescence and DIC) of representative cells. Right: Linear schemes (not drawn to scale) of the 18 
plasmid vectors used for protein expression (Table 1). Gel insets correspond to Western blots of 19 
sedimentation analyses of whole cell lysates from the same cultures, which were then quantitated 20 
(histograms). (C) A Western-blot quantitation of the relative expression levels achieved for the 21 
distinct RepA-WH1 constructs when cloned in pRK2 (mRFP) or p15A (YFP). Samples were whole 22 
lysates from equivalent cell numbers. In all panels, histograms represent the mean intensities of the 23 
distinct protein bands, calculated from three independent experiments. Dilution factors were applied 24 
for gel loading of those samples in which high overexpression levels were achieved (asterisks), to 25 
allow for unsaturated detection. Dilutions were then taken into account for quantitation. Standard 26 
deviations are displayed on each histogram bar. 27 
 28 
  
 
14 
Figure 2. Study of the pairwise co-expression, from compatible pRK2 and p15A vectors (Fig. 1), of 1 
the indicated RepA-WH1 variants in E. coli cells. (A) Two channels fluorescence microscopy plus 2 
DIC imaging. (B) Protein solubility analyses were carried out by sedimentation plus Western-3 
blotting with the indicated tag-specific antibodies. Bottom: Histogram representation of the 4 
intensities of the bands, averaged from three independent expression and blotting experiments. The 5 
intracellular distribution of fluorescent foci and the aggregation/solubility balance point to a series in 6 
the strength/dominance of amyloid aggregation for the RepA-WH1 prionoid: A31V > ∆N37 (IBs)  > 7 
WT. (C) SDD-AGE analysis of intracellular aggregation of the RepA-WH1(WT-mRFP/A31V-YFP) 8 
amyloid variants. Besides protein monomers, more abundant for the WT variant, two distinct 9 
oligomers were evident, having those assembled by RepA-WH1(A31V) a lower size than those 10 
assembled by the WT protein. 11 
 12 
Figure 3. DIC and fluorescence microscopy imaging of bacteria co-expressing either mRFP (red) or 13 
YFP (yellow) as controls for the fluorescent protein reporters, together with the indicated RepA-14 
WH1 partner (WT/A31V/∆N37) fused to the complementary color. 15 
 16 
Table 1. Plasmids used in this study. 17 
 18 
Table 2. Oligonucleotides used in plasmid construction. Relevant stretches (point mutations, 19 
restriction sites) are highlighted as grey capital letters in the forward (F) and reverse (R) primer 20 
sequences. 21 
 22 
Table 3. Quantification of aggregate numbers and cell lengths in microscopy fields captured after 4 23 
h of co-expression of the specified RepA-WH1 pairs. 200 cells of each class were used for these 24 
measurements. 25 
 26 
 
 
 
  
 
 
Plasmid Relevant genotype References 
pACYC184 CR; TcR New England Biolabs 
pSEVA121 AR 15 
p3YFP AR, YFP A. Lindner (CRI-INSERM) 
pRK2-WH1(A31V)-mCherry 
 
repA-WH1(A31V)-mCherry 
+opsp18; AR; lacIq+ 
12 
pRK2-WH1(∆N37)-mCherry 
 
repA-WH1(∆N37)-mCherry 
+opsp18; AR; lacIq+ 
12 
pRK2-WH1(WT)-mCherry 
 
repA-WH1(WT)-mCherry 
+opsp18; AR; lacIq+ 
This work 
pRK2-mCherry 
 
 
p15A-WH1(WT)-YFP 
 
∆repA-WH1-mCherry 
+opsp18; CR; lacIq+ 
 
repA-WH1(WT)-YFPA206K 
+opsp18; CR; lacIq+ 
This work 
 
 
This work 
p15A-WH1(A31V)-YFP 
 
repA-WH1(A31V)-YFPA206K 
+opsp18; CR; lacIq+ 
This work 
p15A-WH1(∆N37)-YFP 
 
repA-WH1(∆N37)-YFPA206K 
+opsp18; CR; lacIq+ 
This work 
 
p15A-YFP 
 
∆repA-WH1-YFPA206K 
+opsp18; CR; lacIq+ 
 
This work 
 
 
 
5’gctTCCGGAatggtgagcaagggcgagg (F)  
 BspEI  YFP cloning (PCR) 
5’gctGGATCCttacttgtacagctcgtccatg (R) 
 BamHI 
 
5’ctttgcccgttatccCgatcatatgaaacgg  
  YFP A206K mutant 
5’ccgtttcatatgatcGggataacgggcaaag  (QuikChange kit, Stratagene) 
 
5’gctACTAGTtgacaattaatcatcggctcg (F) pRK2/Ptac cloning (PCR) 
 SpeI cMyc-YFP & 
5’gctGGATCCttacttgtacagctcgtccatg (R) WH1(WT/A31V/ΔN37)-YFP 
 BamHI 
 
5’gctACTAGTtgacaattaatcatcggctcg (F)  
 SpeI p15A/Ptac cloning (PCR) 
5’agtGAATTCgagctcggtac (R) His6-WH1(WT/A31V/∆N37)-mCherry 
 EcoRI 
 
5’gctcGGTACCtcgatcctctacgccggac (F) pRK2/p15A 
 KpnI 
5’cgagGAATTCtcatgccccgcgcccac (R) pRK2 lacIq cloning (PCR) 
 EcoRI  
5’cgagGAGCTCtcatgccccgcgcccac (R) p15A 
 SacI 
 
 
 
 
 
 
Oligonucleotides Comments 
 
     % Cells with aggregate #    Cell length 
        (µm) 
    0    1    2    3   ≥4  
 
WT-mRFP + WT-YFP 
 
77.5 16 6.5 0 0 2.67 ± 0.79 
 
WT-mRFP + A31V-YFP 
 
0 7 58.5 19.5 15.5 5.07 ± 1.46 
 
WT-mRFP + YFP 
 
100 0 0 0 0 3.87 ± 1.13 
 
WT-mRFP + ΔN37-YFP 
 
0 43 39 13.5 4.5 3.91 ± 1.30 
 
A31V-mRFP + WT-YFP 
 
0 5.5 41.5 33.5 19.5 3.89 ± 1.32 
 
A31V-mRFP + A31V-YFP 
 
0 5 56 20.5 18.5 5.00 ± 1.66 
 
A31V-mRFP + YFP 
 
11 6 37.5 17.5 28 5.25 ± 1.54 
 
A31V-mRFP + ΔN37-YFP 
 
0 9 39.5 27 24.5 5.27 ± 1.58 
 
mRFP + WT-YFP 
 
100 0 0 0 0 2.33 ± 0.49 
 
mRFP + A31V-YFP 
 
0 10 64 21 5 4.91 ± 1.26 
 
mRFP + YFP 
 
100 0 0 0 0 4.23 ± 1.24 
 
mRFP + ΔN37-YFP 
 
0 90 10 0 0 3.21 ± 0.83 
 
ΔN37-mRFP + WT-YFP 
 
45 52.5 2.5 0 0 2.04 ± 0.59 
 
ΔN37-mRFP + A31V-YFP 
 
0 5.5 63.5 18.5 12.5 5.00 ± 1.49 
 
ΔN37-mRFP + YFP 
 
86.5 11.5 2 0 0 3.79 ± 1.15 
 
ΔN37-mRFP + ΔN37-YFP 
 
0 68 27.5 3 1.5 3.33 ± 0.99 
 
